Diatomite biosilica nanocarriers for siRNA transport inside cancer cells

Rea, Ilaria; Martucci, Nicola; Stefano, Luca De; Ruggiero, Immacolata; Terracciano, Monica; Dardano, Principia; Migliaccio, Nunzia; Arcari, Paolo; Tatè, Rosarita; Rendina, Ivo; Lamberti, Annalisa

doi:10.1016/j.bbagen.2014.09.009

Cited by 94 publications

(103 citation statements)

References 34 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…[48][49][50] Previously reported pattern of siRNA release from diatomite demonstrated an initial phase with a burst trend within 12 h; therefore, Bcl2 gene silencing was determined by qRT-PCR 24 h after treatment of cells in the presence of 200 µg/mL DNPs functionalized with pA2036 and a polyArg peptide complexed to siRNA directed against Bcl2 mRNA (DNPs•pA2036•polyArg•siRNABcl2). 17 As depicted in Figure 8A, DNPs•pA2036•polyArg•siRNABcl2 caused a 40.90%±4.5% decrease in the levels of Bcl2 mRNA, whereas only a slight reduction in Bcl2 mRNA expression levels was observed after treatment of cells with the control peptide, DNPs•pRND•polyArg•siRNABcl2 (9.09%±9.70%), relative to untreated cells (negative control). These results were compared to those obtained by transfecting A20 cells using a conventional method (lipofectamine); with respect to basal expression, siRNABcl2 (100 pmol) was able to downregulate the mRNA level by ~10% after 24 h after transfection (data not shown), demonstrating that treatment of A20 cells with DNPs•pA2036•polyArg•siRNABcl2 resulted in more efficient silencing relative to the results achieved using lipofectamine.…”

Section: Cell Viabilitymentioning

confidence: 96%

“…To this end, DNPs were conjugated with pA2036 engineered with a C-terminal stretch of basic amino acids (arginine residues) to promote the formation of siRNA-peptide complexes based on electrostatic interactions; addition of these amino acids also protects the nucleic acid from enzymatic degradation. 17 This approach, illustrated in Figure 4A, was based on the concept that a single molecule could simultaneously load the siRNA and facilitate active targeting by specific Ig-BCR recognition. The mean particle size of DNPs modified in this way, determined by DLS, was 370±20 nm with a negative ζ-potential of −35±1 mV.…”

Section: Targeted Sirna Deliverymentioning

confidence: 99%

“…17 After purification treatments, DNPs were aminosilanized by 1 h incubation at room temperature (RT) with a 5% (v/v) APTES solution in absolute ethanol to form a thin silane film on their surface. 32,33 The amino groups of silanized DNPs were covalently conjugated to the carboxyl groups of peptides alone and/or complexed with siRNA via NHS/EDC chemistry; briefly, DNPs (~1.0 mg) were incubated with 150 µM peptide in the presence of EDC (20 mM)/NHS (12 mM) solution in 10 mM MES buffer pH 5.5 to promote the reaction (ON at RT, under stirring).…”

Section: Preparation Of Modified Dnpsmentioning

confidence: 99%

“…In this study, diatomite-based nanoparticles were employed as a delivery platform to specifically vehiculate siRNA to lymphoma cancer cells. [17][18][19][20] B-cell lymphoma is a clonal expansion of neoplastic cells that can have a fatal outcome. Tumorigenic B-cell lymphomas are sensitive to conventional anticancer treatments, including chemotherapy, radiation, and corticosteroids; however, the disease is associated with incomplete response to clinical treatment, resulting in a minimal residual disease, where some undetected cancerous cells supply the cancer cell reservoir in vivo.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Nanoparticle-based strategy for personalized B-cell lymphoma therapy

Martucci¹,

Migliaccio²,

Ruggiero³

et al. 2016

IJN

Self Cite

View full text Add to dashboard Cite

B-cell lymphoma is associated with incomplete response to treatment, and the development of effective strategies targeting this disease remains challenging. A new personalized B-cell lymphoma therapy, based on a site-specific receptor-mediated drug delivery system, was developed in this study. Specifically, natural silica-based nanoparticles (diatomite) were modified to actively target the antiapoptotic factor B-cell lymphoma/leukemia 2 (Bcl2) with small interfering RNA (siRNA). An idiotype-specific peptide (Id-peptide) specifically recognized by the hypervariable region of surface immunoglobulin B-cell receptor was exploited as a homing device to ensure specific targeting of lymphoma cells. Specific nanoparticle uptake, driven by the Id-peptide, was evaluated by flow cytometry and confocal microscopy and was increased by approximately threefold in target cells compared with nonspecific myeloma cells and when a random control peptide was used instead of Id-peptide. The specific internalization efficiency was increased by fourfold when siRNA was also added to the modified nanoparticles. The modified diatomite particles were not cytotoxic and their effectiveness in downregulation of gene expression was explored using siRNA targeting Bcl2 and evaluated by quantitative real-time polymerase chain reaction and Western blot analyses. The resulting gene silencing observed is of significant biological importance and opens new possibilities for the personalized treatment of lymphomas

show abstract

Section: Cell Viabilitymentioning

confidence: 96%

Section: Targeted Sirna Deliverymentioning

confidence: 99%

Section: Preparation Of Modified Dnpsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Nanoparticle-based strategy for personalized B-cell lymphoma therapy

Martucci¹,

Migliaccio²,

Ruggiero³

et al. 2016

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, after silanization, APTES layer was cured at high temperature [43]. The aminosilane is more reactive, and it can be applied on a surface using pure organic solvent.…”

Section: Chemical Functionalization Proceduresmentioning

confidence: 99%

Bioengineered Surfaces for Real-Time Label-Free Detection of Cancer Cells

Martucci¹,

Migliaccio²,

ImmacolataRuggiero³

et al. 2016

Lab-on-a-Chip Fabrication and Application

Self Cite

View full text Add to dashboard Cite

Biosensing technology is an advancing field that benefits from the properties of biological processes combined to functional materials. Recently, biosensors have emerged as essential tools in biomedical applications, offering advantages over conventional clinical techniques for diagnosis and therapy. Optical biosensors provide fast, selective, direct, and cost-effective analyses allowing label-free and real-time tests. They have also shown exceptional potential for integration in lab-on-a-chip (LOC) devices. The major challenge in the biosensor field is to achieve a fully operative LOC platform that can be used in any place at any time. The choice of an appropriate strategy to immobilize the biological element on the sensor surface becomes the key factor to obtain an applicable analytical tool. In this chapter, after a brief description of the main biofunctionalization procedures on silicon devices, two silicon-based chips that present an (i) IgG antibody or (ii) an Id-peptide as molecular probe, directed against the B-cell receptor of lymphoma cancer cells, will be presented. From a comparison in detecting cells, the Id-peptide device was able to detect lymphoma cells also at low cell concentrations (8.5 × 10 −3 cells/μm 2 ) and in the presence of a large amount of non-specific cells. This recognition strategy could represent a proof-of-concept for an innovative tool for the targeting of patient-specific neoplastic B cells during the minimal residual disease; in addition, it represents an encouraging starting point for the construction of a lab-on-a-chip system for the specific recognition of neoplastic cells in biological fluids enabling the follow-up of the changes of cancer cells number in patients, highly demanded for therapy monitoring applications.

show abstract

Diatom Silica for Biomedical Applications

Maher

Lošić

2019

Diatoms: Fundamentals and Applications

View full text Add to dashboard Cite

Diatomite biosilica nanocarriers for siRNA transport inside cancer cells

Cited by 94 publications

References 34 publications

Nanoparticle-based strategy for personalized B-cell lymphoma therapy

Nanoparticle-based strategy for personalized B-cell lymphoma therapy

Bioengineered Surfaces for Real-Time Label-Free Detection of Cancer Cells

Diatom Silica for Biomedical Applications

Contact Info

Product

Resources

About